clofibric acid has been researched along with Dyslipidemias in 83 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Statin treatment (and possibly niacin when given alone or in combination with statins) appears to be associated with a slightly increased risk of new onset diabetes mellitus (NODM)." | 3.76 | Lipid-lowering agents and new onset diabetes mellitus. ( Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K, 2010) |
| "When treated with atorvastatin, 90% of patients achieved a LDL C<1 g/L, compared to 51% when treated with fibrate (P=0." | 2.74 | Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile. ( Giraudeaux, V; Guillausseau, PJ; Kévorkian, JP; Laloi-Michelin, M; Meas, T; Peynet, J; Virally, M, 2009) |
| "The evidence to support treating dyslipidemia in hemodialysis patients, however, has been mixed, with several outcome trials pending." | 2.44 | Managing dyslipidemia in chronic kidney disease. ( Harper, CR; Jacobson, TA, 2008) |
| " Myopathy, liver enzyme elevations, and cholecystitis have been potential adverse reactions of interest." | 2.44 | Expert commentary: the safety of fibrates in lipid-lowering therapy. ( Brown, WV, 2007) |
| " Endothelial dysfunction and a reduced generation or bioavailability of NO have emerged as major pathophysiological mechanisms in ED." | 2.44 | Dyslipidemia as a risk factor for erectile dysfunction. ( Mikhailidis, DP; Paraskevas, KI; Vrentzos, GE, 2007) |
| "Established treatments of dyslipidemias are statins and fibrates." | 2.44 | The treatment of dyslipidemia--what's left in the pipeline? ( Popescu, L; Rau, O; Schubert-Zsilavecz, M; Steinhilber, D; Zettl, H, 2008) |
| "Vascular complications associated with type 2 diabetes confer significant morbidity and mortality." | 2.44 | Atherosclerosis in type 2 diabetes: a role for fibrate therapy? ( Steiner, G, 2007) |
| "Greater than 60% of patients with type 2 diabetes will have retinopathy." | 2.44 | Update on the treatment of diabetic retinopathy. ( Miller, AG; Wilkinson-Berka, JL, 2008) |
| "Niacin has been shown to regress atherosclerosis when used as monotherapy, in combination with a statin, and in combination with nonstatin therapies (including cholesterol-binding resins) and fibrates." | 2.44 | Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials. ( Taylor, AJ, 2008) |
| "Fifth, combined hyperlipidemia is the most common lipid disorder, has the strongest risk for CVD, and combines elevated LDL, hypertriglyceridemia, and low HDL." | 2.44 | Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. ( Atkinson, B; Dowdy, A; Knopp, RH; Paramsothy, P, 2008) |
| "Thus, targeting the hyperglycemia in type 2 diabetes mellitus (DM) alone will not eliminate all of the excess cardiovascular risk; rather aggressive treatment is needed for all of the modifiable cardiometabolic risk factors." | 2.44 | Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors. ( Gerich, JE, 2007) |
| " This may at least partially explain the lower incidence of myopathy with fenofibrate compared with gemfibrozil when combined with statins." | 2.43 | Fibrates in combination with statins in the management of dyslipidemia. ( Jacobson, TA; Zimmerman, FH, 2006) |
| " This article summarises the mechanisms of action of available lipid lowering agents, their recommended dosing regiments and possible drug interactions." | 2.43 | [Treatment of dyslipidemia in clinical practice]. ( Harangi, M; Paragh, G, 2006) |
| "The metabolic syndrome is a clustering of risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension." | 2.43 | Dyslipidaemia, hypercoagulability and the metabolic syndrome. ( Athyros, VG; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP, 2006) |
| "The metabolic syndrome is a cluster of symptoms that function as risk factors for cardiovascular disease (CVD), and its key components--diabetes, dyslipidemia, and hypertension--form a lethal combination." | 1.36 | Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome. ( Mehta, A, 2010) |
| "The demography of dyslipidemia has changed towards a more complex atherogenic dyslipidemia involving increased levels of LDL cholesterol, in particular highly atherogenic small dense particles, hypertriglyceridemia and low HDL cholesterol, together with increased levels of markers of inflammation, thrombogenesis and endothelial dysfunction." | 1.35 | [Place of fibrates for the treatment of patients with atherogenic dyslipidemia]. ( De Backer, G; Ducobu, J; Hermans, M; Kartounian, J; Legat, P; Maes, M; Scheen, AJ; Van Gaal, L; Velkeniers, B, 2009) |
| "Monotherapy for the treatment of dyslipidemias is commonly insufficient to achieve all lipid targets recommended by current guidelines." | 1.33 | [Drug combinations: statins and fibrates]. ( Xavier, HT, 2005) |
| "The role of dyslipidemia is essential in the development of atherosclerosis, therefore continuing care of dyslipidemic patients is an extremely important task in cardiovascular prevention." | 1.33 | [Continuing care of patients with cardiovascular risk in general practice: patients with dyslipidemia and their care]. ( Ilyés, I; Jancsó, Z; Simay, A; Varga, Z, 2005) |
| "Likewise, the metabolic syndrome is a secondary target of treatment." | 1.32 | CHD risk equivalents and the metabolic syndrome. Trial evidence supports aggressive management. ( Thompson, PD, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 73 (87.95) | 29.6817 |
| 2010's | 10 (12.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sierra, ML | 1 |
| Beneton, V | 1 |
| Boullay, AB | 1 |
| Boyer, T | 1 |
| Brewster, AG | 1 |
| Donche, F | 1 |
| Forest, MC | 1 |
| Fouchet, MH | 1 |
| Gellibert, FJ | 1 |
| Grillot, DA | 1 |
| Lambert, MH | 1 |
| Laroze, A | 1 |
| Le Grumelec, C | 1 |
| Linget, JM | 1 |
| Montana, VG | 1 |
| Nguyen, VL | 1 |
| Nicodème, E | 1 |
| Patel, V | 1 |
| Penfornis, A | 1 |
| Pineau, O | 1 |
| Pohin, D | 1 |
| Potvain, F | 1 |
| Poulain, G | 1 |
| Ruault, CB | 1 |
| Saunders, M | 1 |
| Toum, J | 1 |
| Xu, HE | 1 |
| Xu, RX | 1 |
| Pianetti, PM | 1 |
| Tovar, JM | 1 |
| Bazaldua, OV | 1 |
| Loffredo, A | 1 |
| Harper, CR | 1 |
| Jacobson, TA | 3 |
| Gorkin, JU | 1 |
| Watson, K | 1 |
| Knopp, RH | 2 |
| Zambon, A | 1 |
| Marchiori, M | 1 |
| Manzato, E | 1 |
| Toth, PP | 1 |
| Davidson, M | 1 |
| Cardenas, GA | 1 |
| Lavie, CJ | 1 |
| Cardenas, V | 1 |
| Milani, RV | 1 |
| McCullough, PA | 1 |
| Seth Loomba, R | 1 |
| Arora, R | 1 |
| Tentolouris, N | 1 |
| Eleftheriadou, I | 1 |
| Katsilambros, N | 1 |
| Hughes, S | 1 |
| Gardette, V | 1 |
| Bongard, V | 1 |
| Dallongeville, J | 1 |
| Arveiler, D | 1 |
| Bingham, A | 1 |
| Ruidavets, JB | 1 |
| Amouyel, P | 1 |
| Haas, B | 1 |
| Ducimetière, P | 1 |
| Ferrières, J | 1 |
| Arnaud, J | 1 |
| Akbaraly, TN | 1 |
| Hininger-Favier, I | 1 |
| Berr, C | 1 |
| Roussel, AM | 1 |
| Nair, AP | 1 |
| Darrow, B | 1 |
| Meas, T | 1 |
| Laloi-Michelin, M | 1 |
| Virally, M | 1 |
| Peynet, J | 1 |
| Giraudeaux, V | 1 |
| Kévorkian, JP | 1 |
| Guillausseau, PJ | 1 |
| Avis, HJ | 1 |
| Vissers, MN | 1 |
| Wijburg, FA | 1 |
| Kastelein, JJ | 2 |
| Hutten, BA | 1 |
| Mymin, D | 1 |
| Dembinski, T | 1 |
| Friesen, MH | 1 |
| Merkel, M | 1 |
| Wierzbicki, AS | 3 |
| Mutez, E | 1 |
| Duhamel, A | 1 |
| Defebvre, L | 1 |
| Bordet, R | 1 |
| Destée, A | 1 |
| Kreisler, A | 1 |
| Miller, M | 1 |
| Hausenloy, DJ | 1 |
| Yellon, DM | 1 |
| Guthrie, RM | 1 |
| Thompson, PD | 1 |
| Ginsberg, HN | 1 |
| Maccallum, PR | 1 |
| Sharma, RK | 1 |
| Singh, VN | 1 |
| Reddy, HK | 1 |
| Cybulska, B | 2 |
| Kłosiewicz-Latoszek, L | 2 |
| Okopień, B | 2 |
| Haberka, M | 1 |
| Sierant, M | 1 |
| Davidson, MH | 4 |
| Ducobu, J | 2 |
| Scheen, AJ | 1 |
| Legat, P | 1 |
| De Backer, G | 1 |
| Van Gaal, L | 2 |
| Velkeniers, B | 2 |
| Kartounian, J | 1 |
| Maes, M | 1 |
| Hermans, M | 2 |
| Sniderman, AD | 1 |
| Carmena, R | 1 |
| Ascaso, JF | 1 |
| Nakajima, K | 1 |
| Lalloyer, F | 1 |
| Staels, B | 3 |
| Mehta, A | 1 |
| Athyros, VG | 2 |
| Tziomalos, K | 1 |
| Karagiannis, A | 2 |
| Mikhailidis, DP | 3 |
| Hiukka, A | 1 |
| Maranghi, M | 1 |
| Matikainen, N | 1 |
| Taskinen, MR | 1 |
| Ruiz, J | 1 |
| Judge, EP | 1 |
| Phelan, D | 1 |
| O'Shea, D | 1 |
| Khera, A | 1 |
| McGuire, DK | 1 |
| Mosca, L | 1 |
| Chinetti-Gbaguidi, G | 1 |
| Fruchart, JC | 1 |
| Krysiak, R | 1 |
| Kowalski, J | 1 |
| Madej, A | 1 |
| Belowski, D | 1 |
| Zieliński, M | 1 |
| Herman, ZS | 1 |
| Ashen, MD | 1 |
| Blumenthal, RS | 1 |
| Vergès, B | 1 |
| Chironi, G | 1 |
| Simon, A | 1 |
| Gariepy, J | 1 |
| Balice, M | 1 |
| Del-Pino, M | 1 |
| Levenson, J | 1 |
| Corsini, A | 1 |
| Bellosta, S | 1 |
| Turhan, H | 1 |
| Yetkin, E | 1 |
| Xavier, HT | 1 |
| Zimmerman, FH | 1 |
| Jancsó, Z | 1 |
| Varga, Z | 1 |
| Simay, A | 1 |
| Ilyés, I | 1 |
| Paragh, G | 1 |
| Harangi, M | 1 |
| Rosenson, RS | 1 |
| Schulz, I | 1 |
| Kakafika, AI | 1 |
| Liberopoulos, EN | 1 |
| Tenenbaum, A | 2 |
| Fisman, EZ | 2 |
| Motro, M | 2 |
| Adler, Y | 2 |
| Maiques Galán, A | 1 |
| Shetty, C | 1 |
| Balasubramani, M | 1 |
| Capps, N | 1 |
| Milles, J | 1 |
| Ramachandran, S | 1 |
| Backes, JM | 1 |
| Gibson, CA | 1 |
| Howard, PA | 1 |
| Ascaso, J | 1 |
| Gonzalez Santos, P | 1 |
| Hernandez Mijares, A | 1 |
| Mangas Rojas, A | 1 |
| Masana, L | 1 |
| Millan, J | 1 |
| Pallardo, LF | 1 |
| Pedro-Botet, J | 1 |
| Perez Jimenez, F | 1 |
| Pintó, X | 1 |
| Plaza, I | 1 |
| Rubiés, J | 1 |
| Zúñiga, M | 1 |
| Brown, WV | 1 |
| Armani, A | 1 |
| McKenney, JM | 1 |
| Rizzo, M | 1 |
| Berneis, K | 1 |
| Vrentzos, GE | 1 |
| Paraskevas, KI | 1 |
| Benatar, JR | 1 |
| Stewart, RA | 1 |
| Ballantyne, CM | 1 |
| Rau, O | 1 |
| Zettl, H | 1 |
| Popescu, L | 1 |
| Steinhilber, D | 1 |
| Schubert-Zsilavecz, M | 1 |
| Steiner, G | 1 |
| Wilkinson-Berka, JL | 1 |
| Miller, AG | 1 |
| Fazio, S | 1 |
| Taylor, AJ | 1 |
| Paramsothy, P | 1 |
| Atkinson, B | 1 |
| Dowdy, A | 1 |
| Brown, BG | 1 |
| Zhao, XQ | 1 |
| Paumelle, R | 1 |
| Gerich, JE | 1 |
| Scheen, A | 1 |
| Feeman, WE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study to Assess the Consequences of Postprandial Lipemia in CRP as Inflammatory Marker in High-risk Adults, to Investigate Whether Hypolipidemic, Hypoglycemic or Antihypertensive Medication May Lessen the Exaggerated Postprandial Lipemia and Evaluate th[NCT02163044] | 580 participants (Actual) | Observational | 2014-09-30 | Completed | |||
| Treatment Study for Severe High-Density Lipoprotein Deficiency[NCT00458055] | 19 participants (Actual) | Interventional | 2006-11-30 | Completed | |||
| Effect of Tomato Consumption on Serum High Density Lipoprotein-cholesterol Levels. A Randomized, Open-label, Single Blind, Clinical Trial[NCT01342666] | 50 participants (Actual) | Interventional | 2009-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluate the effect of two daily tomatoes consumption on HDL-c levels. (NCT01342666)
Timeframe: Baseline and after one month
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline HDL-c | Final HDL-c | |
| Cucumber Consumption | 36.8 | 35.8 |
| Tomato Consumption | 36.5 | 41.6 |
53 reviews available for clofibric acid and Dyslipidemias
| Article | Year |
|---|---|
Managing dyslipidemia in chronic kidney disease.
Topics: Algorithms; Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Fatty | 2008 |
Strategies for reducing cardiovascular risk in patients with hypertriglyceridemia.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Exercise; Fa | 2007 |
When high is low: raising low levels of high-density lipoprotein cholesterol.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dyslipidemias; | 2008 |
A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, | 2008 |
The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Topics: Apolipoprotein A-I; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; C | 2008 |
Fibrates: where are we now?
Topics: C-Reactive Protein; Cardiovascular Diseases; Clofibric Acid; Drug Therapy, Combination; Dyslipidemia | 2009 |
The effects of medications used for the management of dyslipidemia on postprandial lipemia.
Topics: Apolipoproteins B; Cholesterol Ester Transfer Proteins; Chylomicrons; Clofibric Acid; Coronary Arter | 2009 |
Lipid management in the geriatric patient.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Coronary Disea | 2009 |
The use of lipid-lowering drug therapy in children and adolescents.
Topics: Adolescent; Atherosclerosis; Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Child; Chole | 2009 |
[Diabetic dyslipoproteinemia: beyond LDL].
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chy | 2009 |
Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Creatinine; Diabetes Me | 2009 |
Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Aci | 2009 |
The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dysli | 2009 |
Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.
Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Drug Therap | 2009 |
[Treatment of lipid disorders in metabolic syndrome and type 2 diabetes. The place for fibrates].
Topics: Clofibric Acid; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypolipidemic Agents; | 2005 |
[Pleiotropic action of ACE-I and fibrates].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiovascular Diseases; Clofibric Acid; Dyslipid | 2005 |
[Combination pharmacotherapy therapy in the management of atherogenic dyslipidemia].
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Clofibric Acid; Drug Therapy, Combination; Dyslipi | 2005 |
[Global therapy of diabetic dyslipidemia: benefits and new therapeutic approaches].
Topics: Clofibric Acid; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymet | 2010 |
Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type | 2010 |
Fibrates, glitazones, and peroxisome proliferator-activated receptors.
Topics: Animals; Blood Glucose; Clofibric Acid; Diabetes Mellitus, Type 2; Drug Discovery; Dyslipidemias; Hi | 2010 |
PPARalpha: an emerging therapeutic target in diabetic microvascular damage.
Topics: Clofibric Acid; Diabetes Mellitus; Dyslipidemias; Hemodynamics; Humans; Microvessels; PPAR alpha | 2010 |
Fibrates: no ACCORD on their use in the treatment of dyslipidaemia.
Topics: Clinical Trials as Topic; Clofibric Acid; Drug Therapy, Combination; Drug-Related Side Effects and A | 2010 |
Beyond statin therapy: a review of the management of residual risk in diabetes mellitus.
Topics: Atherosclerosis; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combinatio | 2010 |
Management of diabetic dyslipidemia: need for reappraisal of the goals.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Complications; Drug Therapy, Combination; Dyslipid | 2005 |
Management of dyslipidemia in women in the post-hormone therapy era.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Die | 2005 |
Pleiotropic effects of fibrates.
Topics: Animals; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Humans; Hypolipidemic Agents; PPAR | 2005 |
Clinical practice. Low HDL cholesterol levels.
Topics: Adult; Alcohol Drinking; Cholesterol; Cholesterol, HDL; Clofibric Acid; Diet, Fat-Restricted; Drug T | 2005 |
Clinical practice. Low HDL cholesterol levels.
Topics: Adult; Alcohol Drinking; Cholesterol; Cholesterol, HDL; Clofibric Acid; Diet, Fat-Restricted; Drug T | 2005 |
Clinical practice. Low HDL cholesterol levels.
Topics: Adult; Alcohol Drinking; Cholesterol; Cholesterol, HDL; Clofibric Acid; Diet, Fat-Restricted; Drug T | 2005 |
Clinical practice. Low HDL cholesterol levels.
Topics: Adult; Alcohol Drinking; Cholesterol; Cholesterol, HDL; Clofibric Acid; Diet, Fat-Restricted; Drug T | 2005 |
Role for fibrate therapy in diabetes: evidence before FIELD.
Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypolipidemic Agents; Metabolic Sy | 2005 |
Fibrates in combination with statins in the management of dyslipidemia.
Topics: Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductas | 2006 |
[Treatment of dyslipidemia in clinical practice].
Topics: Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibric | 2006 |
[Treatment of dyslipidemia: how and when to combine lipid lowering drugs].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Clofibric Acid; Drug Therapy, Combination; D | 2006 |
Dyslipidaemia, hypercoagulability and the metabolic syndrome.
Topics: Adipose Tissue; Adiposity; Animals; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Ac | 2006 |
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxy | 2006 |
Optimal lipid modification: the rationale for combination therapy.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as | 2005 |
Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Topics: Cholesterol, HDL; Clofibric Acid; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibit | 2007 |
Expert commentary: the safety of fibrates in lipid-lowering therapy.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Databases, Factual; Dyslipidemias | 2007 |
Safety considerations with fibrate therapy.
Topics: Cholelithiasis; Clinical Trials as Topic; Clofibric Acid; Creatinine; Drug Therapy, Combination; Dys | 2007 |
The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.
Topics: Bezafibrate; Clofibric Acid; Dyslipidemias; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipi | 2007 |
Dyslipidemia as a risk factor for erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adult; Aged; Clofibric Acid; Cyclic Nucleotide Phosphodiesteras | 2007 |
Is it time to stop treating dyslipidaemia with fibrates?
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiovascular Diseases; Clofibric Acid; Dia | 2007 |
Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors.
Topics: Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Fatty Acids, Omega-3; Humans; Hydroxymethylg | 2007 |
The treatment of dyslipidemia--what's left in the pipeline?
Topics: Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Cl | 2008 |
Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dyslipidemias; Humans; Hydroxymethylgluta | 2007 |
Atherosclerosis in type 2 diabetes: a role for fibrate therapy?
Topics: Atherosclerosis; Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hydroxymethylglut | 2007 |
Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Topics: Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Clofibric Acid; Dysli | 2008 |
Update on the treatment of diabetic retinopathy.
Topics: Adrenal Cortex Hormones; Aldehyde Reductase; Angiotensin II; Antihypertensive Agents; Blood Glucose; | 2008 |
Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Topics: Cardiovascular Diseases; Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Me | 2008 |
Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Clofibric Acid; Coronary Artery Disease; Disease Progres | 2008 |
Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol | 2008 |
Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Aci | 2008 |
Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms.
Topics: Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase | 2008 |
Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors.
Topics: Cardiovascular Diseases; Clofibric Acid; Coronary Artery Disease; Diabetes Complications; Diabetes M | 2007 |
Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates.
Topics: Atherosclerosis; Belgium; Clofibric Acid; Dyslipidemias; Humans; Hypolipidemic Agents; Morbidity; Ri | 2008 |
3 trials available for clofibric acid and Dyslipidemias
| Article | Year |
|---|---|
Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Ty | 2009 |
Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates.
Topics: Adult; Anticholesteremic Agents; C-Reactive Protein; Clofibric Acid; Cytokines; Diabetes Mellitus, T | 2005 |
Field of confusion: future prospects for fibrate therapy in cardiovascular disease.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Diabetes Mellitus, Type 2; Double-Blind | 2006 |
27 other studies available for clofibric acid and Dyslipidemias
| Article | Year |
|---|---|
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
Topics: Animals; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, VLDL; Crystallography, X-Ray; Dogs; Dysl | 2007 |
Diabetic dyslipidemia: a practical guide to therapy.
Topics: Clofibric Acid; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; | 2008 |
[Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy].
Topics: Atherosclerosis; Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases | 2008 |
On the road to better dyslipidemia outcomes.
Topics: Azetidines; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Ezetimibe; Fish Oils; Humans; Hy | 2009 |
Ten-year all-cause mortality in presumably healthy subjects on lipid-lowering drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort).
Topics: Cause of Death; Clofibric Acid; Dyslipidemias; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA | 2009 |
Fibrates but not statins increase plasma selenium in dyslipidemic aged patients--the EVA study.
Topics: Aged; Aging; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Dyslipidemias; Female; Humans; Hydr | 2009 |
Iatrogenic severe depression of high-density lipoprotein cholesterol.
Topics: Aged; Cholesterol, HDL; Clofibric Acid; Dyslipidemias; Female; Humans; Iatrogenic Disease; Male; Mid | 2009 |
Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease.
Topics: Clofibric Acid; Diabetes Complications; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase I | 2009 |
Dyslipidemia and cardiovascular risk: the importance of early prevention.
Topics: Cardiovascular Diseases; Clofibric Acid; Drug Combinations; Dyslipidemias; Fatty Acids, Omega-3; Hum | 2009 |
Reshaping the dyslipidemia management paradigm.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Dyslipidemias; Fe | 2003 |
CHD risk equivalents and the metabolic syndrome. Trial evidence supports aggressive management.
Topics: Adult; Cholesterol, LDL; Clofibric Acid; Coronary Disease; Diabetes Complications; Dyslipidemias; Fe | 2003 |
A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al.
Topics: Animals; Betaine; Bezafibrate; Clofibric Acid; Dyslipidemias; Folic Acid; Homocysteine; Humans; Hypo | 2009 |
[Place of fibrates for the treatment of patients with atherogenic dyslipidemia].
Topics: Atherosclerosis; Clinical Trials as Topic; Clofibric Acid; Dyslipidemias; Humans; Hydroxymethylgluta | 2009 |
Apolipoprotein B, diabetes and medical consensus.
Topics: Apolipoproteins B; Clofibric Acid; Consensus; Diabetes Complications; Diabetes Mellitus; Diabetic An | 2010 |
Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome.
Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductas | 2010 |
Lipid-lowering agents and new onset diabetes mellitus.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus; Dyslipidemias; Evidence-Based Medicine; | 2010 |
[On behalf and the extent of evidence].
Topics: Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, | 2010 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Aci | 2005 |
Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clofibric | 2005 |
Pharmacokinetic interactions between statins and fibrates.
Topics: Area Under Curve; Biological Availability; Clofibric Acid; Drug Combinations; Drug Interactions; Dys | 2005 |
Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?
Topics: Clofibric Acid; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic | 2006 |
[Drug combinations: statins and fibrates].
Topics: Age Factors; Clofibric Acid; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Female; Ge | 2005 |
[Continuing care of patients with cardiovascular risk in general practice: patients with dyslipidemia and their care].
Topics: Adult; Aged; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Continuity | 2005 |
[New indications and therapeutic objectives for dyslipidemia].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Clofibric Acid; Do | 2006 |
Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type | 2007 |
Interpreting clinical trials of diabetic dyslipidaemia: new insights.
Topics: Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipi | 2009 |
Statin-fibrate combination therapy.
Topics: Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductas | 2008 |